keyword
MENU ▼
Read by QxMD icon Read
search

Neoadjuvant chemotherapy bladder cancer

keyword
https://www.readbyqxmd.com/read/29432076/neoadjuvant-chemotherapy-followed-by-radical-surgery-versus-concomitant-chemotherapy-and-radiotherapy-in-patients-with-stage-ib2-iia-or-iib-squamous-cervical-cancer-a-randomized-controlled-trial
#1
Sudeep Gupta, Amita Maheshwari, Pallavi Parab, Umesh Mahantshetty, Rohini Hawaldar, Supriya Sastri Chopra, Rajendra Kerkar, Reena Engineer, Hemant Tongaonkar, Jaya Ghosh, Seema Gulia, Neha Kumar, T Surappa Shylasree, Renuka Gawade, Yogesh Kembhavi, Madhuri Gaikar, Santosh Menon, Meenakshi Thakur, Shyam Shrivastava, Rajendra Badwe
Purpose We compared the efficacy and toxicity of neoadjuvant chemotherapy followed by radical surgery versus standard cisplatin-based chemoradiation in patients with locally advanced squamous cervical cancer. Patients and Methods This was a single-center, phase III, randomized controlled trial ( ClinicalTrials.gov identifier: NCT00193739). Eligible patients were between 18 and 65 years old and had stage IB2, IIA, or IIB squamous cervical cancer. They were randomly assigned, after stratification by stage, to receive either three cycles of neoadjuvant chemotherapy using paclitaxel and carboplatin once every 3 weeks followed by radical hysterectomy or standard radiotherapy with concomitant cisplatin once every week for 5 weeks...
February 12, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29430507/peri-operative-chemotherapy-for-bladder-cancer-a-survey-of-providers-to-determine-barriers-and-enablers
#2
Melanie Walker, R Christopher Doiron, Simon D French, Kelly Brennan, Deb Feldman-Stewart, D Robert Siemens, William J Mackillop, Christopher M Booth
Background: Utilization of chemotherapy for patients with muscle-invasive bladder cancer (MIBC) is low. In earlier qualitative work we used the Theoretical Domains Framework (TDF) to determine barriers and enablers of chemotherapy use. In this project we aimed to determine the prevalence of these barriers and enablers in Canadian physicians. Methods: Practicing Canadian urologists, medical oncologists (MOs) and radiation oncologists (ROs) participated in a specialty-specific web-based quantitative survey to assess potential barriers and enablers to chemotherapy use...
January 20, 2018: Bladder Cancer
https://www.readbyqxmd.com/read/29430502/immune-responses-to-neoadjuvant-chemotherapy-in-muscle-invasive-bladder-cancer
#3
REVIEW
Amir Sherif, Malin Winerdal, Ola Winqvist
The secondary effects of chemotherapy, with bone marrow depression and risk of leukopenia, has traditionally been considered being detrimental for the immune system. However, growing evidence suggests a main role for chemotherapy in antitumor immunomodulation. With reference to cisplatin, which is the basis of neoadjuvant chemotherapy in muscle invasive bladder cancer, four different aspects of immunomodulation has thus far been described; increased MHC class I expression, recruitment and proliferation of effector cells, enhancement of tumor-lytic activity of cytotoxic effectors and downregulation of immunosuppressive actors in the microenvironment...
January 20, 2018: Bladder Cancer
https://www.readbyqxmd.com/read/29387556/pretreatment-neutrophil-to-lymphocyte-ratio-predicts-worse-survival-outcomes-and-advanced-tumor-staging-in-patients-undergoing-radical-cystectomy-for-bladder-cancer
#4
Yu Guang Tan, Ernest Eu, Weber Lau Kam On, Hong Hong Huang
Objective: To determine the role of neutrophil-to-lymphocyte ratio (NLR) in prognosticating survival outcomes in patients with advanced/metastatic urothelial bladder cancer. Methods: We retrospectively reviewed 84 patients undergoing radical cystectomy (RC) for UCB from January 2002 to June 2012. NLR was computed (median: 5 days) prior to surgery. No patients received neoadjuvant chemotherapy. NLR was analyzed as a continuous variable and a cut-off point of 2.7 was obtained, with a statistical receiver operating characteristics of 0...
October 2017: Asian Journal of Urology
https://www.readbyqxmd.com/read/29384523/a-practical-guide-to-bladder-cancer-pathology
#5
REVIEW
Eva Compérat, Justine Varinot, Julien Moroch, Caroline Eymerit-Morin, Fadi Brimo
Pathological assessment of bladder cancer is becoming an increasingly complex task owing to the growing availability of molecular data for different histological subtypes and the appreciation of their importance in determining outcomes of neoadjuvant chemotherapy. Urologists are aware of the need to closely collaborate with pathologists, and comprehensive sharing of information is crucial to achieve optimal patient management. Numerous steps towards this goal have been made during the past years. Important advances in the assessment and reporting of grading and staging, especially substaging of pT1 urothelial carcinomas, have been made...
January 31, 2018: Nature Reviews. Urology
https://www.readbyqxmd.com/read/29370182/correlation-of-pathological-complete-response-with-survival-after-neoadjuvant-chemotherapy-in-gastric-or-gastroesophageal-junction-cancer-treated-with-radical-surgery-a-meta-analysis
#6
Ziyu Li, Fei Shan, Yinkui Wang, Yan Zhang, Lianhai Zhang, Shuangxi Li, Yongning Jia, Kan Xue, Rulin Miao, Zhemin Li, Jiafu Ji
BACKGROUND: Neoadjuvant chemotherapy before radical gastrectomy is preferred for locally advanced gastric cancer. To avoid the problematic use of pTNM for patients after neoadjuvant chemotherapy, the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) gastric cancer TNM staging system (8th edition) added ypTNM for the first time. But patients achieving pathological complete response were not covered by the new ypTNM staging system. To investigate whether pathological complete response is associated with better outcome in gastric cancer, as was reported in rectal, breast and bladder cancer...
2018: PloS One
https://www.readbyqxmd.com/read/29368231/surgical-treatment-for-clinical-node-positive-bladder-cancer-patients-treated-with-radical-cystectomy-without-neoadjuvant-chemotherapy
#7
Marco Moschini, Agostino Mattei, Julian Cornelius, Shahrokh F Shariat, Paolo Dell'Oglio, Emanuele Zaffuto, Andrea Salonia, Francesco Montorsi, Alberto Briganti, Renzo Colombo, Andrea Gallina
OBJECTIVE: Growing literature supports good survival expectancies in bladder cancer (BCa) patients affected by clinical node metastases (cN+) treated with multimodal therapy. We evaluated the role of adjuvant chemotherapy in cN+BCa patients treated with radical cystectomy (RC) and pelvic lymph node dissection (PLND) without neoadjuvant chemotherapy (NAC). METHODS: We evaluated a total of 192 patients with BCa and cN+. All patients were treated with RC and PLND without NAC between 2001 and 2013...
January 24, 2018: World Journal of Urology
https://www.readbyqxmd.com/read/29354494/do-we-have-biomarkers-to-predict-response-to-neoadjuvant-and-adjuvant-chemotherapy-and-immunotherapy-in-bladder-cancer
#8
REVIEW
Felix Wezel, Stefan Vallo, Florian Roghmann
Radical cystectomy (RC) is the standard of care treatment of localized muscle-invasive bladder cancer (BC). However, about 50% of patients develop metastases within 2 years after cystectomy. Neoadjuvant cisplatin-based chemotherapy before cystectomy improves the overall survival (OS) in patients with muscle-invasive BC. Pathological response to neoadjuvant treatment is a strong predictor of better disease-specific survival. Nevertheless, some patients do not benefit from chemotherapy. The identification of reliable biomarkers enabling clinicians to identify patients who might benefit from chemotherapy is a very important clinical task...
December 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/29354492/peri-operative-chemotherapy-for-muscle-invasive-bladder-cancer-status-quo-in-2017
#9
REVIEW
Benjamin Pradère, Constance Thibault, Malte W Vetterlein, Jeffrey J Leow, Benoit Peyronnet, Morgan Rouprêt, Thomas Seisen
The role of perioperative chemotherapy associated with radical cystectomy (RC) for muscle-invasive bladder cancer has been analyzed in several landmark randomized controlled trials (RCTs) over the past decades. With regard to neoadjuvant chemotherapy (NAC), a meta-analysis of level 1 evidence and long-term results from the largest RCTs support its use, which is currently advocated as the standard of care by most of the clinical guidelines worldwide. However, with regard to the delivery of adjuvant chemotherapy (AC), evidence is more contentious...
December 2017: Translational Andrology and Urology
https://www.readbyqxmd.com/read/29329894/neoadjuvant-dose-dense-mvac-versus-gc-in-patients-with-ct3-4an0m0-bladder-cancer-treated-with-radical-cystectomy
#10
Homayoun Zargar, Jay B Shah, Bas W van Rhijn, Siamak Daneshmand, Trinity J Bivalacqua, Philippe E Spiess, Peter C Black, Wassim Kassouf
BACKGROUND: Level I evidence supports the utility of neoadjuvant cisplatin-based chemotherapy (NAC) for muscle invasive bladder cancer (BCa). Since dose dense (ddMVAC) has mostly replaced traditional MVAC, we aimed to compare pathological response and survival rates in patients with locally advanced BCa receiving NAC with ddMVAC versus GC. METHODS: We retrospectively reviewed records of patients with urothelial cancer who received NAC and underwent cystectomy at 20 contributing institutions from 2000-2015...
January 9, 2018: Journal of Urology
https://www.readbyqxmd.com/read/29305205/associations-between-travel-distance-hospital-volume-and-outcomes-following-radical-cystectomy-in-patients-with-muscle-invasive-bladder-cancer
#11
Leilei Xia, Benjamin L Taylor, Ronac Mamtani, John P Christodouleas, Thomas J Guzzo
OBJECTIVE: To explore the associations between travel distance, hospital volume, and outcomes following radical cystectomy (RC) for muscle-invasive bladder cancer (MIBC) METHODS: The 2006 to 2013 National Cancer Database (NCDB) was queried to identify patients with MIBC who underwent RC. Multivariable regressions alternately including travel distance, hospital volume, and both in the models were used. Travel distances and hospital volumes were categorized by quartiles. Outcomes of interest were overall survival and quality-of-care indicators...
January 2, 2018: Urology
https://www.readbyqxmd.com/read/29302738/comparison-between-the-diagnostic-accuracies-of-18f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-and-conventional-imaging-in-recurrent-urothelial-carcinomas-a-retrospective-multicenter-study
#12
Fabio Zattoni, Elena Incerti, Michele Colicchia, Paolo Castellucci, Stefano Panareo, Maria Picchio, Federico Fallanca, Alberto Briganti, Marco Moschini, Andrea Gallina, Jeffrey R Karnes, Val Lowe, Stefano Fanti, Riccardo Schiavina, Ilaria Rambaldi, Vincenzo Ficarra, Laura Evangelista
PURPOSE: To determine the performance accuracy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) after primary tumor treatment for both bladder cancer (BC) and upper tract urothelial cancer (UTUC). To compare the accuracy of FDG PET/CT with that of contrast-enhanced-ceCT and magnetic resonance imaging (MRI). METHODS: Data of patients with recurrent urothelial carcinomas (UC) after primary treatment were collected in a retrospective, international multicenter study...
January 4, 2018: Abdominal Radiology
https://www.readbyqxmd.com/read/29281852/evolution-of-cystectomy-care-over-a-11-years-period-in-a-high-volume-tertiary-referral-center
#13
Aldo Brassetti, Axel Möller, Oscar Laurin, Jonas Höijer, Christofer Adding, Ayako Miyakawa, Abolfazl Hosseini, Peter Wiklund
OBJECTIVES: To describe the evolution RC care over 11 years in a referral center. MATERIALS AND METHODS: Clinical data of patients undergoing either open RC (ORC) or robot-assisted RC (RARC) for cT1-4aN0M0 bladder cancer (BCa) at our center between 01/2006 and 12/2016 were retrospectively evaluated. Crude and propensity score weighted log-binomial regression analyses assessed the association between pre-/perioperative variables and the risk of reoperation, intensive care unit (ICU) admission and death within 90 days after RC...
December 27, 2017: BJU International
https://www.readbyqxmd.com/read/29259186/mutational-patterns-in-chemotherapy-resistant-muscle-invasive-bladder-cancer
#14
David Liu, Philip Abbosh, Daniel Keliher, Brendan Reardon, Diana Miao, Kent Mouw, Amaro Weiner-Taylor, Stephanie Wankowicz, Garam Han, Min Yuen Teo, Catharine Cipolla, Jaegil Kim, Gopa Iyer, Hikmat Al-Ahmadie, Essel Dulaimi, David Y T Chen, R Katherine Alpaugh, Jean Hoffman-Censits, Levi A Garraway, Gad Getz, Scott L Carter, Joaquim Bellmunt, Elizabeth R Plimack, Jonathan E Rosenberg, Eliezer M Van Allen
Despite continued widespread use, the genomic effects of cisplatin-based chemotherapy and implications for subsequent treatment are incompletely characterized. Here, we analyze whole exome sequencing of matched pre- and post-neoadjuvant cisplatin-based chemotherapy primary bladder tumor samples from 30 muscle-invasive bladder cancer patients. We observe no overall increase in tumor mutational burden post-chemotherapy, though a significant proportion of subclonal mutations are unique to the matched pre- or post-treatment tumor, suggesting chemotherapy-induced and/or spatial heterogeneity...
December 19, 2017: Nature Communications
https://www.readbyqxmd.com/read/29232021/investigation-of-diffusion-kurtosis-imaging-for-discriminating-tumors-from-inflammatory-lesions-after-treatment-for-bladder-cancer
#15
Fang Wang, Di Jin, Xiao-Lan Hua, Zi-Zhou Zhao, Lian-Ming Wu, Wei-Bo Chen, Guang-Yu Wu, Xiao-Xi Chen, Hai-Ge Chen
BACKGROUND: The bladder wall may thicken resulting from chronic inflammation after initial treatment (transurethral resection [TUR] or neoadjuvant chemotherapy), which may mimic the feature of recurrent or residual bladder tumors (RBT). Therefore, it is critical to discriminate RBT from benign lesions after initial treatment. PURPOSE: To investigate whether diffusion kurtosis imaging (DKI) could discriminate RBT from post-therapy bladder inflammatory lesions. STUDY TYPE: Retrospective...
December 12, 2017: Journal of Magnetic Resonance Imaging: JMRI
https://www.readbyqxmd.com/read/29226744/the-role-of-adjuvant-chemotherapy-in-locally-advanced-bladder-cancer
#16
Waqar Haque, Gary D Lewis, Vivek Verma, Jorge G Darcourt, E Brian Butler, Bin S Teh
PURPOSE: The standard of care for locally advanced bladder cancer (LABC) is neoadjuvant chemotherapy followed by cystectomy. However, the role of adjuvant therapy is unclear. The purpose of this study was to evaluate the outcomes of adjuvant chemotherapy for patients with LABC following neoadjuvant chemotherapy and cystectomy, and to determine whether select patients may benefit from adjuvant chemotherapy. METHODS: The National Cancer Data Base (NCDB) was queried (2004-2013) for patients with newly diagnosed pT3-4N0-3M0 bladder cancer that received neoadjuvant chemotherapy and cystectomy...
December 11, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29185045/preoperative-chronic-kidney-disease-is-predictive-of-oncological-outcome-of-radical-cystectomy-for-bladder-cancer
#17
Akihiko Matsumoto, Tohru Nakagawa, Atsushi Kanatani, Masaomi Ikeda, Taketo Kawai, Jimpei Miyakawa, Satoru Taguchi, Akihiro Naito, Masafumi Otsuka, Yasukazu Nakanishi, Motofumi Suzuki, Fumitaka Koga, Yasushi Nagase, Yasushi Kondo, Toshikazu Okaneya, Yoshinori Tanaka, Hideyo Miyazaki, Tetsuya Fujimura, Hiroshi Fukuhara, Haruki Kume, Yasuhiko Igawa, Yukio Homma
PURPOSE: To evaluate the impact of preoperative chronic kidney disease (CKD) on oncological outcomes after radical cystectomy (RC) for bladder cancer. METHODS: We reviewed the medical records of patients with urothelial bladder carcinoma who underwent RC with curative intent at seven hospitals between 1990 and 2013. After excluding patients with a history of upper urinary tract urothelial cancer or neoadjuvant chemotherapy, we analyzed 594 cases for the study. Preoperative estimated glomerular filtration rate (eGFR) was calculated using the three-variable Japanese equation for GFR estimation from serum creatinine level and age...
November 28, 2017: World Journal of Urology
https://www.readbyqxmd.com/read/29169845/impact-of-adequate-pelvic-lymph-node-dissection-on-overall-survival-after-radical-cystectomy-a-stratified-analysis-by-clinical-stage-and-receipt-of-neoadjuvant-chemotherapy
#18
Nicolas von Landenberg, Jacqueline M Speed, Alexander P Cole, Thomas Seisen, Stuart R Lipsitz, Philipp Gild, Mani Menon, Adam S Kibel, Florian Roghmann, Joachim Noldus, Maxine Sun, Quoc-Dien Trinh
PURPOSE: An adequate pelvic lymph node dissection (LND) during radical cystectomy (RC) for muscle-invasive bladder cancer (BCa) has been shown to provide a survival benefit. We designed a study to assess the effect of adequate LND on overall survival (OS) according to cT stage and receipt of neoadjuvant chemotherapy (NAC). MATERIAL AND METHODS: We identified 16,505 patients with localized BCa who received RC in the National Cancer Database (2004-2012). Inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier and Cox regression analyses were used to compare OS between patients who received adequate LND (defined as ≥10 nodes removed) and those who did not, stratified by cT stage and receipt of NAC...
November 20, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/29156782/trends-in-neoadjuvant-chemotherapy-use-and-oncological-outcomes-for-muscle-invasive-bladder-cancer-in-japan-a-multicenter-study
#19
Go Anan, Shingo Hatakeyama, Naoki Fujita, Hiromichi Iwamura, Toshikazu Tanaka, Hayato Yamamoto, Yuki Tobisawa, Tohru Yoneyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Takuya Koie, Hiroyuki Ito, Kazuaki Yoshikawa, Toshiaki Kawaguchi, Makoto Sato, Chikara Ohyama
Objective: Despite benefits of neoadjuvant chemotherapy (NAC), the adoption of guideline recommendations for NAC use in patients with muscle-invasive bladder cancer (MIBC) has been slow. We aimed to evaluate temporal trends in NAC use and oncological outcomes in a representative cohort of patients with MIBC. Methods: We included 532 patients from 4 hospitals who underwent radical cystectomy (RC) for ≥ cT2 MIBC in 1996-2017. We retrospectively evaluated temporal changes in NAC use and progression-free and overall survival...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29154041/patient-characteristics-treatment-patterns-and-prognostic-factors-in-squamous-cell-bladder-cancer
#20
Haris Zahoor, Paul Elson, Andrew Stephenson, Georges-Pascal Haber, Jihad Kaouk, Amr Fergany, Byron Lee, Vadim Koshkin, Moshe Ornstein, Timothy Gilligan, Jorge A Garcia, Brian Rini, Petros Grivas
BACKGROUND: Squamous cell carcinoma (SCC) is an uncommon histologic subtype of bladder cancer with limited data on treatment patterns, outcomes, and prognostic factors. "Real world" information might inform decision-making, prognostic estimates, and clinical trial designs. PATIENTS AND METHODS: A retrospective review of patients with tissue-confirmed bladder SCC treated at Cleveland Clinic from 2007 to 2016 was performed. Data on patient characteristics, treatment patterns, and clinical follow-up were extracted...
October 17, 2017: Clinical Genitourinary Cancer
keyword
keyword
40909
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"